Literature DB >> 861384

Basis and results of chemotherapeutic treatment of gliomas.

D C Crafts, C B Wilson.   

Abstract

Brain tumor chemotherapy has improved in recent years with increasing knowledge of the requirements for effective drugs (such as lipophilicity and low molecular weight in order to enter brain tissue, and ability to kill proliferating and non-proliferating cells) and the evolution of criteria for statistically evaluable studies. In Phase II studies BCNU is the best single agent so far, giving a response rate of 51 per 100 for a median duration of 9 months. CCNU and procarbazine are also effective, while epipodophyllotoxin, DTIC, BIC, methotrexate and vincristine are somewhat less so. Recent Phase III studies have shown unequivocally that radiotherapy is effective; BCNU and radiation therapy together appear at present the best available treatment following surgery. Combinations of drugs as well as new drugs are a major source of hope for the future in these tumors with their still inexorably fatal courses.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 861384

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  2 in total

1.  Intracarotid infusion of PCNU (NSC: 95466): preclinical toxicological study in dogs.

Authors:  L Goumnerova; M T Richard; D Addison; V Montpetit; D J Stewart
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

2.  Combination chemotherapy (COMP protocol) and radiotherapy of anaplastic supratentorial gliomas.

Authors:  K Jellinger; P Kothbauer; D Volc; R Vollmer; R Weiss
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.